[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"low-anterior-resection-syndrome-lars\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:low-anterior-resection-syndrome-lars":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,40,72],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100651328","early-implementation-of-sacral-neuromodulation-in-patients-with-low-anterior-resection-syndrome-100651328",false,"NCT07761884","Early Implementation of Sacral Neuromodulation in Patients With Low Anterior Resection Syndrome.","Early Implementation of Sacral Neuromodulation in Patients With Low Anterior Resection Syndrome: a Randomized, Multicenter, Prospective, Open-label, Pragmatic Study.","Inclusion Criteria:\n\n* Adult patients (18 years of age or older) who are capable of signing the appropriate informed consent form.\n* Patients who have undergone an anterior rectal resection for rectal cancer, with an anastomosis, whether or not they have received neoadjuvant therapy, and who have bowel function, either via a direct anastomosis or following reconstruction of a lateral ileostomy.\n* Patients who experience more than 6 episodes of urgency and\u002For incontinence in the following two weeks after the screening visit, as recorded in a daily bowel diary.\n* Patients with a LARS score \\>21 points (major or minor LARS).\n* Patients who report at least one symptom and one consequence as defined by the international definition.\n\nExclusion Criteria:\n\n* Metastatic disease at the time of surgery.\n* Need for adjuvant chemotherapy at the time of assessment.\n* Active chemotherapy.\n* Patients with an ileostomy.\n* Intellectual or language-related difficulty in answering the questionnaires.\n* Refusal to participate in the study or failure to commit to follow-up visits.\n* Patients with contraindications for sacral neuromodulation implantation (those with pacemakers, active infections, or allergies to prosthetic materials).\n* Patients with active inflammatory bowel disease at the time of surgery.\n* Patients who have undergone other intestinal resections in addition to rectal resection.","ALL","18 Years",{"count":19,"type":20},40,"ESTIMATED","INTERVENTIONAL",[23],"NA","A randomized, prospective, multicenter, open-label, pragmatic pilot study of patients with Low Anterior Resection Syndrome treated early (\\\u003C120 days after discharge following intestinal bypass reconstruction) with sacral nerve root neuromodulation, compared with another group receiving personalized conservative treatment as performed in routine clinical practice.",[26],"Low Anterior Resection Syndrome (LARS)","NOT_YET_RECRUITING","2026-08-10",{"date":30,"type":31},"2026-08-12","ACTUAL",{"date":33,"type":20},"2026-08",{"date":35,"type":20},"2030-02",{"name":37,"class":38},"Hospital Universitari Vall d'Hebron Research Institute","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":21,"phases":50,"briefSummary":51,"conditions":52,"keywords":53,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":4},"100646049","evaluating-the-optimal-timing-of-trans-anal-irrigation-for-low-anterior-resection-syndrome-post-rectal-cancer-surgery-100646049","NCT07696689","Evaluating the Optimal Timing of Trans-Anal Irrigation for Low Anterior Resection Syndrome Post-rectal Cancer Surgery","Evaluating the Optimal Timing of Trans-Anal Irrigation for Low Anterior Resection Syndrome Post-rectal Cancer Surgery - An Italian Multicentre Randomised Study","EARLY-TAI","Inclusion Criteria:\n\n* Adults aged ≥ 18 years\n* Colorectal resection for rectal cancer with a protective ostomy\n* Integrity of the colorectal or coloanal anastomosis, as confirmed by each center's standard procedure\n* LARS score \\> 30 (major LARS)\n* Not previously treated with TAI (except for enemas)\n* Completion of training on TAI irrigation by trained medical\u002Fnursing staff\n* Use of only the Peristeen® Plus device for TAI\n* Written informed consent\n\nExclusion Criteria:\n\n* Neurological diseases\n* Psychiatric disorders\n* Refusal to consent to follow-up\n* Current or planned pregnancy\n* Known allergy to latex\n* Presence of contraindications as outlined in the device's Instructions for Use (IFU), such as ischemic colitis, acute inflammatory bowel disease, or acute diverticulitis.",{"count":49,"type":20},250,[23],"This study aims to evaluate the optimal timing of trans-anal irrigation (TAI) for participants with low anterior resection syndrome (LARS) who have undergone surgery for rectal cancer.\n\nThe main question it aims to answer is:\n\n\"Can starting TAI within three months of stoma closure reduce the number of daily bowel movements in people who have undergone rectal surgery?\" Researchers will compare the outcomes for participants who start TAI within the first three months with those who start after three months, to see if early TAI can reduce the number of daily bowel movements more effectively than starting later.\n\nThe study will also determine whether early TAI can improve typical bowel symptoms, enhance quality of life, and increase satisfaction with treatment as much as when it is performed more than three months after stoma closure.\n\nParticipants will:\n\n* Undergo a preliminary visit to assess their eligibility to participate\n* Undergo training to understand how to use the device correctly\n* Perform regular TAI\n* Undergo four control visits at 1, 3, 6 and 9 months after the start of treatment.",[26],[54,55,56,57,58,59,60,61,62],"LARS","Trans-Anal Irrigation","Rectal Cancer","Low Anterior Resection Syndrome","Constipation","Bowel movements","Fecal incontinence","TAI","Peristeen Plus","2026-07-08",{"date":65,"type":31},"2026-07-10",{"date":67,"type":20},"2026-09",{"date":69,"type":20},"2029-06",{"name":71,"class":38},"Simona Ascanelli",{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":21,"phases":81,"briefSummary":82,"conditions":83,"keywords":88,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":105},"100643035","efficacy-and-safety-of-transcutaneous-posterior-tibial-nerve-stimulation-on-fecal-continence-in-patients-undergoing-surgery-for-rectal-neoplasia-100643035","NCT07632196","Efficacy and Safety of Transcutaneous Posterior Tibial Nerve Stimulation on Fecal Continence in Patients Undergoing Surgery for Rectal Neoplasia","Randomized Clinical Trial Assessing the Efficacy and Safety of Transcutaneous Posterior Tibial Nerve Stimulation on Fecal Continence in Patients Undergoing Surgery for Rectal Neoplasia","Inclusion Criteria:\n\n\\- Adult patients diagnosed with rectal neoplasia and who have undergone a high anterior rectal resection regardless of the surgical approach (open, laparoscopic, laparoscopic+TaTME or robotic+TaTME).\n\nExclusion Criteria:\n\n* Patients not operated or within active surveillance strategy programs (watch \\& wait)\n* Patients with ostomy\n* Patients with contraindications to the use of the neurostimulator:\n\n  * Pacemaker \u002F Defibrillator \u002F Other electronic devices\n  * History of heart problems\n  * Propensity to excessive bleeding (coagulopathies)\n  * Damage to the nervous system (epilepsy)\n  * Current pregnancy\n  * Infections or skin lesions\n  * Severe vascular disorders\n  * Active neoplasms.",{"count":80,"type":20},84,[23],"Rectal neoplasia is one of the most prevalent cancers in Spain, and the treatment of choice is total mesorectal excision (TME), as it has demonstrated significant oncological improvements. However, mesorectal excision is not without complications, and patients often experience altered bowel function in the form of low anterior resection syndrome (LARS), as well as erectile dysfunction. However, few studies evaluate faecal incontinence, as most focus on oncological outcomes.\n\nThe aim of our study is to evaluate the efficacy and safety of posterior tibial nerve stimulation on fecal incontinence, sexual dysfunction, and quality of life in patients who underwent to rectal surgery for rectal neoplasia.\n\nIt will be conducted a randomized clinical trial (1:1) with two arms: half of the patients will receive posterior tibial nerve stimulation, while the other half will undergo stimulation with subtherapeutic doses. Faecal incontinence will be assessed using the LARS and Wexner questionnaires, and quality of life and sexual function will be assessed using the Fecal Incontinence Quality of Life Scale (FIQLS) and the Colorectal Cancer Quality of Life Questionnaire (QLQ-CR38), at one month, six months and one year after surgery.",[26,84,85,86,87],"Rectal Neoplasm Malignant","Quality of Life (QOL)","Fecal Incontinence (FI)","Disorder of Ejaculation",[89,90,91,92,93,94,86],"total mesorectum excision","rectal neoplasm","randomised clinical trial","posterior tibial nerve stimulation","low anterior resection syndrome (LARS)","life quality","RECRUITING","2026-06-02",{"date":98,"type":31},"2026-06-08",{"date":100,"type":31},"2026-02-06",{"date":102,"type":20},"2028-12-31",{"name":104,"class":38},"Althaia Xarxa Assistencial Universitària de Manresa",2]